Comprehensive Stock Comparison
Compare Editas Medicine, Inc. (EDIT) vs Arrowhead Pharmaceuticals, Inc. (ARWR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ARWR | 232.6% revenue growth vs EDIT's -58.6% |
| Quality / Margins | ARWR | 18.5% net margin vs EDIT's -430.8% |
| Stability / Safety | ARWR | Beta 1.67 vs EDIT's 2.10 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ARWR | +234.6% vs EDIT's +14.6% |
| Efficiency (ROA) | ARWR | 12.6% ROA vs EDIT's -99.1%, ROIC 7.2% vs -120.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Editas Medicine is a clinical-stage biotechnology company developing CRISPR-based gene editing therapies for serious genetic diseases. It generates revenue primarily through research collaborations and licensing agreements — with potential future income from drug sales if its therapies gain regulatory approval. The company's key advantage is its proprietary CRISPR gene editing platform and intellectual property portfolio in the rapidly evolving genome editing space.
Arrowhead Pharmaceuticals is a biotechnology company that develops RNA interference (RNAi) therapeutics for intractable diseases. It generates revenue primarily through research collaborations and licensing agreements with pharmaceutical partners — including upfront payments, milestone payments, and royalties on future sales — while advancing its own pipeline of clinical-stage candidates. The company's key advantage is its proprietary Targeted RNAi Molecule (TRiM™) platform, which enables precise delivery of RNAi therapeutics to specific tissues and cells.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ARWR leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). EDIT leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
ARWR is the larger business by revenue, generating $1.1B annually — 23.5x EDIT's $46M. ARWR is the more profitable business, keeping 18.5% of every revenue dollar as net income compared to EDIT's -4.3%. On growth, EDIT holds the edge at +122.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EDITEditas Medicine, … | ARWRArrowhead Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $46M | $1.1B |
| EBITDAEarnings before interest/tax | -$193M | $326M |
| Net IncomeAfter-tax profit | -$200M | $202M |
| Free Cash FlowCash after capex | -$181M | $322M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +99.4% |
| Operating MarginEBIT ÷ Revenue | -4.3% | +27.6% |
| Net MarginNet income ÷ Revenue | -4.3% | +18.5% |
| FCF MarginFCF ÷ Revenue | -3.9% | +29.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +122.7% | +104.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +62.7% | +115.8% |
Valuation Metrics
| Metric | EDITEditas Medicine, … | ARWRArrowhead Pharmac… |
|---|---|---|
| Market CapShares × price | $205M | $8.7B |
| Enterprise ValueMkt cap + debt − cash | $109M | $9.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.76x | -5186.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 76.09x |
| Price / SalesMarket cap ÷ Revenue | 6.35x | 10.48x |
| Price / BookPrice ÷ Book value/share | 1.35x | 16.81x |
| Price / FCFMarket cap ÷ FCF | — | 55.41x |
Profitability & Efficiency
ARWR delivers a 35.9% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-15 for EDIT. EDIT carries lower financial leverage with a 0.26x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARWR's 1.66x. On the Piotroski fundamental quality scale (0–9), ARWR scores 5/9 vs EDIT's 2/9, reflecting solid financial health.
| Metric | EDITEditas Medicine, … | ARWRArrowhead Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -14.9% | +35.9% |
| ROA (TTM)Return on assets | -99.1% | +12.6% |
| ROICReturn on invested capital | -120.8% | +7.2% |
| ROCEReturn on capital employed | -71.7% | +8.6% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.26x | 1.66x |
| Net DebtTotal debt minus cash | -$97M | $611M |
| Cash & Equiv.Liquid assets | $132M | $227M |
| Total DebtShort + long-term debt | $35M | $838M |
| Interest CoverageEBIT ÷ Interest expense | -27.46x | 3.83x |
Total Returns (with DRIP)
A $10,000 investment in ARWR five years ago would be worth $7,552 today (with dividends reinvested), compared to $469 for EDIT. Over the past 12 months, ARWR leads with a +234.6% total return vs EDIT's +14.6%. The 3-year compound annual growth rate (CAGR) favors ARWR at 25.1% vs EDIT's -37.6% — a key indicator of consistent wealth creation.
| Metric | EDITEditas Medicine, … | ARWRArrowhead Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +7.3% | -6.7% |
| 1-Year ReturnPast 12 months | +14.6% | +234.6% |
| 3-Year ReturnCumulative with dividends | -75.7% | +95.9% |
| 5-Year ReturnCumulative with dividends | -95.3% | -24.5% |
| 10-Year ReturnCumulative with dividends | -92.4% | +1522.3% |
| CAGR (3Y)Annualised 3-year return | -37.6% | +25.1% |
Risk & Volatility
ARWR is the less volatile stock with a 1.67 beta — it tends to amplify market swings less than EDIT's 2.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARWR currently trades 82.4% from its 52-week high vs EDIT's 48.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EDITEditas Medicine, … | ARWRArrowhead Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 1.67x |
| 52-Week HighHighest price in past year | $4.54 | $76.76 |
| 52-Week LowLowest price in past year | $0.91 | $9.57 |
| % of 52W HighCurrent price vs 52-week peak | +48.5% | +82.4% |
| RSI (14)Momentum oscillator 0–100 | 61.2 | 46.7 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 2.5M |
Analyst Outlook
Wall Street rates EDIT as "Buy" and ARWR as "Buy". Consensus price targets imply 484.1% upside for EDIT (target: $13) vs 24.5% for ARWR (target: $79).
| Metric | EDITEditas Medicine, … | ARWRArrowhead Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $12.85 | $78.78 |
| # AnalystsCovering analysts | 24 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Editas Medicine, In… (EDIT) | 100 | 8.85 | -91.2% |
| Arrowhead Pharmaceu… (ARWR) | 100 | 205.63 | +105.6% |
Arrowhead Pharmaceu… (ARWR) returned -24% over 5 years vs Editas Medicine, In… (EDIT)'s -95%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Editas Medicine, In… (EDIT) | $6M | $32M | +433.9% |
| Arrowhead Pharmaceu… (ARWR) | $158333.00 | $829M | +523763.0% |
Arrowhead Pharmaceuticals, Inc.'s revenue grew from $0M (2016) to $829M (2025) — a 159.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Editas Medicine, In… (EDIT) | -16.1% | -7.3% | +54.3% |
| Arrowhead Pharmaceu… (ARWR) | -516.1% | -0.2% | +100.0% |
Arrowhead Pharmaceuticals, Inc.'s net margin went from -516% (2016) to -0% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Editas Medicine, In… (EDIT) | -3.02 | -2.88 | +4.6% |
| Arrowhead Pharmaceu… (ARWR) | -1.34 | -0.01 | +99.1% |
Arrowhead Pharmaceuticals, Inc.'s EPS grew from $-1.34 (2016) to $-0.01 (2025).
Chart 5Free Cash Flow — 5 Years
Editas Medicine, Inc. generated $-219M FCF in 2024 (-28% vs 2021). Arrowhead Pharmaceuticals, Inc. generated $157M FCF in 2025 (+6% vs 2021).
EDIT vs ARWR: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is EDIT or ARWR a better buy right now?
Analysts rate Editas Medicine, Inc. (EDIT) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EDIT or ARWR?
Over the past 5 years, Arrowhead Pharmaceuticals, Inc. (ARWR) delivered a total return of -24.5%, compared to -95.3% for Editas Medicine, Inc. (EDIT). A $10,000 investment in ARWR five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARWR returned +1522% versus EDIT's -92.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EDIT or ARWR?
By beta (market sensitivity over 5 years), Arrowhead Pharmaceuticals, Inc. (ARWR) is the lower-risk stock at 1.67β versus Editas Medicine, Inc.'s 2.10β — meaning EDIT is approximately 26% more volatile than ARWR relative to the S&P 500. On balance sheet safety, Editas Medicine, Inc. (EDIT) carries a lower debt/equity ratio of 26% versus 166% for Arrowhead Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — EDIT or ARWR?
Arrowhead Pharmaceuticals, Inc. (ARWR) is the more profitable company, earning -0.2% net margin versus -733.7% for Editas Medicine, Inc. — meaning it keeps -0.2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARWR leads at 11.9% versus -777.2% for EDIT. At the gross margin level — before operating expenses — EDIT leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — EDIT or ARWR?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is EDIT or ARWR better for a retirement portfolio?
For long-horizon retirement investors, Arrowhead Pharmaceuticals, Inc. (ARWR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1522% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2.10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARWR: +1522%, EDIT: -92.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between EDIT and ARWR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.